Multivariate analysis of prognostic factors for induction of CR, and the probabilities of OS, RFS, and EFS
| Variable . | HR . | 95% CI . | P . |
|---|---|---|---|
| CR | |||
| Treatment arm | |||
| SD-DN | 1 | ||
| HD-DN | 1.802 | 1.080-3.005 | .024 |
| Karnofsky performance score | |||
| ≥ 90 | 1 | ||
| < 90 | 0.321 | 0.175-0.588 | < .001 |
| Cytogenetic risk group | < .001 | ||
| Good | 1 | ||
| Intermediate | 0.177 | 0.067-0.468 | < .001 |
| Poor | 0.093 | 0.031-0.278 | < .001 |
| Unknown | 0.219 | 0.030-1.577 | .132 |
| OS | |||
| Treatment arm | |||
| SD-DN | 1 | ||
| HD-DN | 0.739 | 0.560-0.974 | .032 |
| Age, y | |||
| ≤ 40 | 1 | ||
| > 40 | 1.475 | 1.112-1.956 | .007 |
| Leukemia | |||
| De novo | 1 | ||
| Secondary | 2.010 | 1.128-3.580 | .018 |
| Karnofsky performance score | |||
| ≥ 90 | 1 | ||
| < 90 | 1.764 | 1.257-2.475 | .001 |
| Uric acid, mg/dL | |||
| < 7.0 | 1 | ||
| ≥ 7.0 | 1.701 | 1.135-2.547 | .010 |
| Cytogenetic risk group | < .001 | ||
| Good | 1 | ||
| Intermediate | 1.632 | 1.103-2.415 | .014 |
| Poor | 3.692 | 2.348-5.806 | < .001 |
| Unknown | 1.769 | 0.540-5.796 | .346 |
| RFS | |||
| Age, y | |||
| ≤ 40 | 1 | ||
| > 40 | 1.442 | 1.043-1.993 | .027 |
| Uric acid, mg/dL | |||
| < 7.0 | 1 | ||
| ≥ 7.0 | 2.026 | 1.305-3.146 | .002 |
| Cytogenetic risk group | < .001 | ||
| Good | 1 | ||
| Intermediate | 1.098 | 0.745-1.618 | .636 |
| Poor | 2.510 | 1.542-4.085 | < .001 |
| Unknown | 0.527 | 0.072-3.853 | .528 |
| EFS | |||
| Treatment arm | |||
| SD-DN | 1 | ||
| HD-DN | 0.774 | 0.600-0.998 | .048 |
| Age, y | |||
| ≤ 40 | 1 | ||
| > 40 | 1.404 | 1.079-1.826 | .011 |
| Karnofsky performance score | |||
| ≥ 90 | 1 | ||
| < 90 | 1.908 | 1.390-2.619 | < .001 |
| Uric acid, mg/dL | |||
| < 7.0 | 1 | ||
| ≥ 7.0 | 1.707 | 1.176-2.479 | .005 |
| Cytogenetic risk group | < .001 | ||
| Good | 1 | ||
| Intermediate | 1.503 | 1.062-2.128 | .021 |
| Poor | 3.162 | 2.078-4.810 | < .001 |
| Unknown | 1.176 | 0.363-3.808 | .786 |
| Variable . | HR . | 95% CI . | P . |
|---|---|---|---|
| CR | |||
| Treatment arm | |||
| SD-DN | 1 | ||
| HD-DN | 1.802 | 1.080-3.005 | .024 |
| Karnofsky performance score | |||
| ≥ 90 | 1 | ||
| < 90 | 0.321 | 0.175-0.588 | < .001 |
| Cytogenetic risk group | < .001 | ||
| Good | 1 | ||
| Intermediate | 0.177 | 0.067-0.468 | < .001 |
| Poor | 0.093 | 0.031-0.278 | < .001 |
| Unknown | 0.219 | 0.030-1.577 | .132 |
| OS | |||
| Treatment arm | |||
| SD-DN | 1 | ||
| HD-DN | 0.739 | 0.560-0.974 | .032 |
| Age, y | |||
| ≤ 40 | 1 | ||
| > 40 | 1.475 | 1.112-1.956 | .007 |
| Leukemia | |||
| De novo | 1 | ||
| Secondary | 2.010 | 1.128-3.580 | .018 |
| Karnofsky performance score | |||
| ≥ 90 | 1 | ||
| < 90 | 1.764 | 1.257-2.475 | .001 |
| Uric acid, mg/dL | |||
| < 7.0 | 1 | ||
| ≥ 7.0 | 1.701 | 1.135-2.547 | .010 |
| Cytogenetic risk group | < .001 | ||
| Good | 1 | ||
| Intermediate | 1.632 | 1.103-2.415 | .014 |
| Poor | 3.692 | 2.348-5.806 | < .001 |
| Unknown | 1.769 | 0.540-5.796 | .346 |
| RFS | |||
| Age, y | |||
| ≤ 40 | 1 | ||
| > 40 | 1.442 | 1.043-1.993 | .027 |
| Uric acid, mg/dL | |||
| < 7.0 | 1 | ||
| ≥ 7.0 | 2.026 | 1.305-3.146 | .002 |
| Cytogenetic risk group | < .001 | ||
| Good | 1 | ||
| Intermediate | 1.098 | 0.745-1.618 | .636 |
| Poor | 2.510 | 1.542-4.085 | < .001 |
| Unknown | 0.527 | 0.072-3.853 | .528 |
| EFS | |||
| Treatment arm | |||
| SD-DN | 1 | ||
| HD-DN | 0.774 | 0.600-0.998 | .048 |
| Age, y | |||
| ≤ 40 | 1 | ||
| > 40 | 1.404 | 1.079-1.826 | .011 |
| Karnofsky performance score | |||
| ≥ 90 | 1 | ||
| < 90 | 1.908 | 1.390-2.619 | < .001 |
| Uric acid, mg/dL | |||
| < 7.0 | 1 | ||
| ≥ 7.0 | 1.707 | 1.176-2.479 | .005 |
| Cytogenetic risk group | < .001 | ||
| Good | 1 | ||
| Intermediate | 1.503 | 1.062-2.128 | .021 |
| Poor | 3.162 | 2.078-4.810 | < .001 |
| Unknown | 1.176 | 0.363-3.808 | .786 |